ReviewNature reviews. Endocrinology2011
Neuroendocrine neoplasms of the gut and pancreas: new insights.
Review in Nature reviews. Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 95 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pathogenesis, diagnosis and treatment of primary renal well-differentiated neuroendocrine tumors: a review of the literature.Frontiers in oncology · 2024Pooled it
- Laparoscopic versus open distal pancreatectomy for pancreatic cancer.The Cochrane database of systematic reviews · 2016Pooled it
- Current state of knowledge on neuroendocrine small bowel tumours: non-systematic review of the literature based on one case.BMJ case reports · 2013Pooled it
- Pooled it
- Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.Annals of nuclear medicine · 2026Trial
- Article
- CREBBP Mutation as a Culprit for Negative SSTR2 PET in Neuroendocrine Tumors.Molecular imaging and biology · 2025Article
- LncRNA PCAT6 promotes progression and metastasis of colonic neuroendocrine carcinomaWorld journal of gastrointestinal oncology · 2025Article
- Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation.Frontiers in oncology · 2025Article
- Neuroendocrine neoplasms as a lynch syndrome manifestation: a case report and comprehensive literature review.Frontiers in endocrinology · 2025Review
- A case-based review of urachal carcinoma with mixed small cell neuroendocrine and adenocarcinoma components, with one new case report and analysis of nine published cases.Frontiers in endocrinology · 2025Review
- The Role of Small-Bowel Endoscopy in the Diagnosis and Management of Small-Bowel Neuroendocrine Tumours.Journal of clinical medicine · 2024Review
- Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment.EJNMMI reports · 2024Article
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Application of Machine Learning in Predicting Hepatic Metastasis or Primary Site in Gastroenteropancreatic Neuroendocrine Tumors.Current oncology (Toronto, Ont.) · 2023Article
- Panic at the Bile Duct: How Intrahepatic Cholangiocytes Respond to Stress and Injury.The American journal of pathology · 2023Review
- Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.Endocrine pathology · 2023Article
- The Surgical and Therapeutic Activities of Non-Functional Pancreatic Neuroendocrine Tumors at a High-Volume Institution.Cancers · 2023Article
- Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon.Medical oncology (Northwood, London, England) · 2022Review
- Updates on Diagnostic and Therapeutic Management of Gastrointestinal and Pancreatic NET.Cancers · 2022Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms arise in almost every organ of the body and are variably defined according to the site of origin. This Review focuses on neuroendocrine neoplasms of the digestive tract and pancreas. The 2010 WHO classification of tumors of the digestive system introduces grading and staging tools for neuroendocrine neoplasms. A carcinoid is now defined as a grade 1 or 2 neuroendocrine tumor and grade 3, small-cell or large-cell carcinomas are defined as neuroendocrine carcinoma. Epidemiological data show a worldwide increase in the prevalence and incidence of gastroentero-pancreatic neuroendocrine tumors in the past few decades, which is probably due to improved methods of detection of these tumors. The current diagnostic procedures and treatment options for neuroendocrine neoplasms are defined and summarized in the Review, although evidence-based data are lacking. Surgery remains the treatment mainstay and somatostatin analogues the basis for both diagnosis and therapy as the only 'theranostic' tool. Emerging compounds including chemotherapeutic agents, small molecules and biological therapies may provide new hope for patients.
Indexed as
Identifiers
21808296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.